Biology Driven Design (BDD) technology platform

Search documents
Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL
Prnewswireยท 2025-07-08 11:00
Core Insights - Evogene Ltd. has successfully completed the divestiture of the majority of its ag-biologicals subsidiary, Lavie Bio Ltd., to ICL Group Ltd., which includes the transfer of Evogene's MicroBoost AI for AG platform [1][2][4] - The transaction encompasses Lavie Bio's proprietary Biology Driven Design technology platform, microbial bank, advanced development programs, and current commercial products, along with core personnel transferring to ICL [2][4] - Existing strategic partnerships and commercial agreements of Lavie Bio will remain under its ownership, potentially generating future revenues for its shareholders [3] Company Strategy - The divestment aligns with Evogene's broader corporate strategy to unlock the intrinsic value of its subsidiaries and technology [4] - ICL aims to enhance its position in the global ag-biologicals market by integrating Lavie Bio's capabilities with its own R&D expertise and sales network, thereby advancing sustainable agricultural solutions [4] Technological Overview - Evogene utilizes three technological engines: MicroBoost AI, ChemPass AI, and GeneRator AI, focusing on the discovery and development of products based on microbes, small molecules, and genetic elements respectively [5] - The company aims to revolutionize life-science product development by leveraging big data and artificial intelligence to increase success rates while reducing development time and costs [5]